HUP0301031A2 - Degradálható nukleinsavpróbák, és eljárások nukleinsavak kimutatására - Google Patents
Degradálható nukleinsavpróbák, és eljárások nukleinsavak kimutatására Download PDFInfo
- Publication number
- HUP0301031A2 HUP0301031A2 HU0301031A HUP0301031A HUP0301031A2 HU P0301031 A2 HUP0301031 A2 HU P0301031A2 HU 0301031 A HU0301031 A HU 0301031A HU P0301031 A HUP0301031 A HU P0301031A HU P0301031 A2 HUP0301031 A2 HU P0301031A2
- Authority
- HU
- Hungary
- Prior art keywords
- probe
- nucleic acid
- region
- probes
- branch
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 107
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 57
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 57
- 108020004711 Nucleic Acid Probes Proteins 0.000 title claims abstract description 35
- 239000002853 nucleic acid probe Substances 0.000 title claims abstract description 33
- 238000001514 detection method Methods 0.000 title abstract description 15
- 239000000523 sample Substances 0.000 claims abstract description 386
- 230000000295 complement effect Effects 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 48
- 238000009396 hybridization Methods 0.000 claims abstract description 36
- 238000006731 degradation reaction Methods 0.000 claims abstract description 27
- 230000007515 enzymatic degradation Effects 0.000 claims abstract description 7
- 238000004132 cross linking Methods 0.000 claims description 92
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 108090000790 Enzymes Proteins 0.000 claims description 28
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 26
- 239000011616 biotin Substances 0.000 claims description 13
- 229960002685 biotin Drugs 0.000 claims description 13
- 235000020958 biotin Nutrition 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 230000015556 catabolic process Effects 0.000 claims description 12
- 125000006853 reporter group Chemical group 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 claims description 8
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 7
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 7
- LDRUKBXKOFTVNA-UHFFFAOYSA-N 7-(2,3-dihydroxypropoxy)chromen-2-one Chemical compound C1=CC(=O)OC2=CC(OCC(O)CO)=CC=C21 LDRUKBXKOFTVNA-UHFFFAOYSA-N 0.000 claims description 6
- ZXLJWZULPBXHSY-UHFFFAOYSA-N pyrano[2,3-g]chromene-2,7-dione Chemical compound O1C(=O)C=CC2=C1C=C1C=CC(=O)OC1=C2 ZXLJWZULPBXHSY-UHFFFAOYSA-N 0.000 claims description 6
- PMLMHGKSGPOBAX-UHFFFAOYSA-N pyrano[3,2-g]chromene-2,8-dione Chemical compound C1=CC(=O)OC2=C1C=C1C=CC(=O)OC1=C2 PMLMHGKSGPOBAX-UHFFFAOYSA-N 0.000 claims description 6
- -1 aryl olefin Chemical class 0.000 claims description 5
- 150000004775 coumarins Chemical class 0.000 claims description 5
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 claims description 4
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 claims description 4
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- 229960002045 bergapten Drugs 0.000 claims description 4
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 claims description 4
- 229960004469 methoxsalen Drugs 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 150000003230 pyrimidines Chemical class 0.000 claims description 4
- 229960000956 coumarin Drugs 0.000 claims description 3
- 235000001671 coumarin Nutrition 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical group C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims 1
- DWAOUXYZOSPAOH-UHFFFAOYSA-N 4-[2-(diethylamino)ethoxy]furo[3,2-g]chromen-7-one;hydrochloride Chemical compound [Cl-].O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC[NH+](CC)CC DWAOUXYZOSPAOH-UHFFFAOYSA-N 0.000 claims 1
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 claims 1
- 238000012790 confirmation Methods 0.000 claims 1
- 238000011330 nucleic acid test Methods 0.000 claims 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 47
- 102000053602 DNA Human genes 0.000 description 45
- 239000000243 solution Substances 0.000 description 35
- 239000002585 base Substances 0.000 description 30
- 229920002477 rna polymer Polymers 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 150000003833 nucleoside derivatives Chemical class 0.000 description 16
- 101710163270 Nuclease Proteins 0.000 description 15
- 239000000376 reactant Substances 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 12
- 239000002718 pyrimidine nucleoside Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000002777 nucleoside Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 10
- 108091028664 Ribonucleotide Proteins 0.000 description 9
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 230000009871 nonspecific binding Effects 0.000 description 9
- 150000003212 purines Chemical class 0.000 description 9
- 239000002336 ribonucleotide Substances 0.000 description 9
- 125000002652 ribonucleotide group Chemical group 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 101100426754 Caenorhabditis elegans try-5 gene Proteins 0.000 description 8
- 239000005547 deoxyribonucleotide Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 125000003835 nucleoside group Chemical group 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 238000006471 dimerization reaction Methods 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 108010068698 spleen exonuclease Proteins 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 108060002716 Exonuclease Proteins 0.000 description 5
- 241000192041 Micrococcus Species 0.000 description 5
- 108010010677 Phosphodiesterase I Proteins 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 102000013165 exonuclease Human genes 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 108091060211 Expressed sequence tag Proteins 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 4
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006862 enzymatic digestion Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000007899 nucleic acid hybridization Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 108091036055 CccDNA Proteins 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108020004518 RNA Probes Proteins 0.000 description 3
- 239000003391 RNA probe Substances 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000006552 photochemical reaction Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 239000002212 purine nucleoside Substances 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XUQUNBOKLNVMMK-UHFFFAOYSA-N [5-[6-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxyhexylcarbamoyl]-6'-(2,2-dimethylpropanoyloxy)-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl] 2,2-dimethylpropanoate Chemical compound C12=CC=C(OC(=O)C(C)(C)C)C=C2OC2=CC(OC(=O)C(C)(C)C)=CC=C2C21OC(=O)C1=CC(C(=O)NCCCCCCOP(N(C(C)C)C(C)C)OCCC#N)=CC=C21 XUQUNBOKLNVMMK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/551,305 US6573048B1 (en) | 2000-04-18 | 2000-04-18 | Degradable nucleic acid probes and nucleic acid detection methods |
| PCT/US2001/012701 WO2001079563A2 (en) | 2000-04-18 | 2001-04-18 | Degradable nucleic acid probes and nucleic acid detection methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0301031A2 true HUP0301031A2 (hu) | 2003-07-28 |
Family
ID=24200719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0301031A HUP0301031A2 (hu) | 2000-04-18 | 2001-04-18 | Degradálható nukleinsavpróbák, és eljárások nukleinsavak kimutatására |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6573048B1 (https=) |
| EP (1) | EP1280938A2 (https=) |
| JP (1) | JP2004501615A (https=) |
| KR (1) | KR20030005289A (https=) |
| CN (1) | CN1432069A (https=) |
| CA (1) | CA2406096A1 (https=) |
| CZ (1) | CZ20023749A3 (https=) |
| HU (1) | HUP0301031A2 (https=) |
| MX (1) | MXPA02010283A (https=) |
| PL (1) | PL362928A1 (https=) |
| WO (1) | WO2001079563A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002059137A1 (en) * | 2000-11-03 | 2002-08-01 | Isis Pharmaceuticals, Inc. | Nuclease-based method for detecting and quantitating oligonucleotides |
| EP1513958B1 (en) | 2002-06-14 | 2011-08-10 | Gen-Probe Incorporated | Compositions for detecting hepatitis b virus |
| US8575327B2 (en) * | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| EP2290071B1 (en) * | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US20060078894A1 (en) * | 2004-10-12 | 2006-04-13 | Winkler Matthew M | Methods and compositions for analyzing nucleic acids |
| CA2857881A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| JP4712814B2 (ja) * | 2005-11-17 | 2011-06-29 | 独立行政法人科学技術振興機構 | 特定の塩基配列の標的核酸類を検出する方法、及び検出のための核酸類セット |
| US20080131878A1 (en) * | 2006-12-05 | 2008-06-05 | Asuragen, Inc. | Compositions and Methods for the Detection of Small RNA |
| EP2104734A2 (en) * | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
| WO2008073915A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
| CA2671270A1 (en) * | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
| US20090232893A1 (en) * | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| JP2010529966A (ja) * | 2007-06-08 | 2010-09-02 | アシュラジェン インコーポレイテッド | 治療的介入の標的としてｍｉＲ−３４によって調節される遺伝子および経路 |
| US8361714B2 (en) * | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| US20090186015A1 (en) * | 2007-10-18 | 2009-07-23 | Latham Gary J | Micrornas differentially expressed in lung diseases and uses thereof |
| US8071562B2 (en) | 2007-12-01 | 2011-12-06 | Mirna Therapeutics, Inc. | MiR-124 regulated genes and pathways as targets for therapeutic intervention |
| WO2009126726A1 (en) * | 2008-04-08 | 2009-10-15 | Asuragen, Inc | Methods and compositions for diagnosing and modulating human papillomavirus (hpv) |
| US8258111B2 (en) * | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
| WO2010056577A1 (en) * | 2008-11-17 | 2010-05-20 | Magic Technologies, Inc. | Methods and compositions in particle-based detection of target molecules using linking molecules |
| US9469868B2 (en) * | 2008-11-17 | 2016-10-18 | Headway Technologies, Inc. | Methods and compositions in particle-based detection of target molecules using covalent bond forming reactive pairs |
| WO2012112563A2 (en) | 2011-02-16 | 2012-08-23 | Magic Technologies, Inc. | Methods and compositions for the target-localized anchoring of detectable label |
| WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
| CN102703584B (zh) * | 2012-04-20 | 2013-08-21 | 中国人民解放军第四军医大学 | 自组装聚合分支dna探针的制备方法 |
| US9738925B2 (en) * | 2013-03-15 | 2017-08-22 | Lyle J. Arnold | Methods for immobilizing target nucleic acids utilizing combinatorial capture probes |
| JP6210484B2 (ja) * | 2013-06-25 | 2017-10-11 | 国立大学法人北陸先端科学技術大学院大学 | 鎖交換された二重鎖オリゴヌクレオチドの製造方法 |
| GB201401885D0 (en) * | 2014-02-04 | 2014-03-19 | Olink Ab | Proximity assay with detection based on hybridisation chain reaction (HCR) |
| TWI710633B (zh) | 2014-11-10 | 2020-11-21 | 美商阿尼拉製藥公司 | Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法 |
| GB2570412A (en) * | 2016-08-31 | 2019-07-24 | Harvard College | Methods of generating libraries of nucleic acid sequences for detection via fluorescent in situ sequencing |
| US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| CA3106701A1 (en) | 2018-08-13 | 2020-02-20 | Alnylam Pharmaceuticals, Inc. | Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof |
| WO2020076976A1 (en) | 2018-10-10 | 2020-04-16 | Readcoor, Inc. | Three-dimensional spatial molecular indexing |
| CN110295235A (zh) * | 2019-07-26 | 2019-10-01 | 合肥欧创基因生物科技有限公司 | 一种双标记探针及其在snp分型及肿瘤突变的应用 |
| WO2021155063A1 (en) | 2020-01-29 | 2021-08-05 | Readcoor, Llc | Compositions and methods for analyte detection |
| US20220049303A1 (en) | 2020-08-17 | 2022-02-17 | Readcoor, Llc | Methods and systems for spatial mapping of genetic variants |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599303A (en) * | 1983-12-12 | 1986-07-08 | Hri Associates, Inc. | Nucleic acid hybridization assay employing probes crosslinkable to target sequences |
| US4826967A (en) | 1987-06-16 | 1989-05-02 | Naxcor | Psoralen-nucleoside adducts and method for their preparation |
| US5403711A (en) * | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
| US6004826A (en) * | 1988-07-20 | 1999-12-21 | David Segev | Repair-mediated process for amplifying and detecting nucleic acid sequences |
| US5082934A (en) | 1989-04-05 | 1992-01-21 | Naxcor | Coumarin derivatives for use as nucleotide crosslinking reagents |
| US5767259A (en) * | 1994-12-27 | 1998-06-16 | Naxcor | Oligonucleotides containing base-free linking groups with photoactivatable side chains |
| WO1994024120A1 (en) | 1993-04-13 | 1994-10-27 | Naxcor | Non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents |
| US5616464A (en) | 1994-12-27 | 1997-04-01 | Naxcor | Nucleic acid sequence detection employing amplification probes |
| US5843650A (en) * | 1995-05-01 | 1998-12-01 | Segev; David | Nucleic acid detection and amplification by chemical linkage of oligonucleotides |
| AU724506B2 (en) | 1995-11-03 | 2000-09-21 | Naxcor | Double-stranded conformational polymorphism analysis |
| CN1285879A (zh) | 1998-01-09 | 2001-02-28 | 美国3M公司 | 可特异性酶切断裂的多核苷酸底物和测试方法 |
| WO1999042616A1 (en) | 1998-02-20 | 1999-08-26 | Dade Behring Inc. | Methods for determining concentrations of nucleic acids |
| US6124099A (en) * | 1998-06-22 | 2000-09-26 | The University Of Vermont And State Agricultural College | Method for placing a photo-cross-linking agent at specific internal sites within the sequence of synthetic strands of ribonucleic acids |
| US6303799B1 (en) | 1998-11-10 | 2001-10-16 | Naxcor | Polynucleotide crosslinking agents |
-
2000
- 2000-04-18 US US09/551,305 patent/US6573048B1/en not_active Expired - Fee Related
-
2001
- 2001-04-18 PL PL01362928A patent/PL362928A1/xx unknown
- 2001-04-18 KR KR1020027014025A patent/KR20030005289A/ko not_active Withdrawn
- 2001-04-18 WO PCT/US2001/012701 patent/WO2001079563A2/en not_active Ceased
- 2001-04-18 CA CA002406096A patent/CA2406096A1/en not_active Abandoned
- 2001-04-18 CN CN01810638A patent/CN1432069A/zh active Pending
- 2001-04-18 MX MXPA02010283A patent/MXPA02010283A/es unknown
- 2001-04-18 JP JP2001576947A patent/JP2004501615A/ja active Pending
- 2001-04-18 EP EP01932581A patent/EP1280938A2/en not_active Withdrawn
- 2001-04-18 HU HU0301031A patent/HUP0301031A2/hu unknown
- 2001-04-18 CZ CZ20023749A patent/CZ20023749A3/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1432069A (zh) | 2003-07-23 |
| CA2406096A1 (en) | 2001-10-25 |
| US6573048B1 (en) | 2003-06-03 |
| EP1280938A2 (en) | 2003-02-05 |
| KR20030005289A (ko) | 2003-01-17 |
| MXPA02010283A (es) | 2003-05-23 |
| WO2001079563A2 (en) | 2001-10-25 |
| WO2001079563A3 (en) | 2002-09-19 |
| PL362928A1 (en) | 2004-11-02 |
| CZ20023749A3 (cs) | 2003-04-16 |
| JP2004501615A (ja) | 2004-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0301031A2 (hu) | Degradálható nukleinsavpróbák, és eljárások nukleinsavak kimutatására | |
| US5681943A (en) | Method for covalently linking adjacent oligonucleotides | |
| JP2856804B2 (ja) | 標識された相補的核酸プローブを開裂する触媒反応の補因子としての活性に基づく核酸配列検出のための触媒ハイブリッド形成系 | |
| EP2920320B1 (en) | Rca reporter probes and their use in detecting nucleic acid molecules | |
| CN101918596B (zh) | 多重基因组获得和丢失分析 | |
| JP4510626B2 (ja) | 脱塩基部位エンドヌクレアーゼアッセイ | |
| JP2005502346A (ja) | 核酸配列の非特異的ハイブリダイゼーションをブロックするための方法 | |
| WO2012016357A1 (en) | Microarray-based assay integrated with particles for analyzing molecular interactions | |
| WO2008002920A2 (en) | Methods for generating target nucleic acid sequences | |
| US20210269865A1 (en) | Methods for Attaching Cellular Constituents to a Matrix | |
| WO2007106802A2 (en) | Method for linear amplification of bisulfite converted dna | |
| JP2010521142A (ja) | 遺伝子発現アッセイ | |
| US6596489B2 (en) | Methods and compositions for analyzing nucleotide sequence mismatches using RNase H | |
| JP2005500051A (ja) | 比率に基づくオリゴヌクレオチドプローブの選択 | |
| CN116194591A (zh) | 序列转换反应 | |
| US20060240431A1 (en) | Oligonucletide guided analysis of gene expression | |
| US20150111774A1 (en) | Method for Detecting Target Nucleic Acid | |
| AU2001259096A1 (en) | Degradable nucleic acid probes and nucleic acid detection methods |